Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 4—April 2007
Letter

VIM-2–producing Pseudomonas putida, Buenos Aires

Marisa Almuzara*, Marcela Radice*, Natalia de Gárate*, Alejandra Kossman*, Arabela Cuirolo*, Gisela Santella*, Angela Famiglietti*, Gabriel Gutkind*Comments to Author , and Varolos Vay*
Author affiliations: *Universidad de Buenos Aires, Buenos Aires, Argentina;

Main Article

Table

Antimicrobial drug susceptibility profiles of 2 blaVIM-2-carrying Pseudomonas putida isolates, Argentina

Drug MIC (μg/mL)
Isolate 1 Isolate 2
Imipenem 32 64
Meropenem 64 64
Ertapenem 128 128
Piperacillin 64 64
Piperacillin-tazobactam 32 32
Ceftazidime 128 128
Cefepime 32 32
Aztreonam 64 64
Amikacin 4 4
Gentamicin 16 16
Ciprofloxacin >64 >64
Gatifloxacin >64 >64
Levofloxacin >64 >64
Moxifloxacin >64 >64
Doxycycline 64 64
Colistin 2 2

Main Article

Page created: June 28, 2010
Page updated: June 28, 2010
Page reviewed: June 28, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external